OTC Watch

All stocks / ELTP

ELITE PHARMACEUTICALS INC /NV/ ELTP

Elite Pharmaceuticals INC /nv/ (ELTP): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated float OTCQBNew Jersey, USA
Live quote on OTC Markets

Market listing

Full name
ELITE PHARMACEUTICALS INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 16
Website
www.elitepharma.com
Source: Stockwatch, 2026-11-17

News headlines

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and Provides Conference Call Information
2026-11-12 16:39 · News Release
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter of Fiscal Year 2027 Financial Results on November 13, 2026
2026-11-10 14:55 · News Release
Elite Pharmaceuticals Expands Board of Directors with Election of Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq.
2026-11-03 07:31 · News Release
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information
2026-08-13 16:12 · News Release
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
2026-08-10 16:55 · News Release
Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL
2026-08-04 07:01 · News Release
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026 and Provides Conference Call Information
2026-06-29 16:30 · News Release
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2026 Financial Results on June 30, 2026
2026-06-23 07:01 · News Release
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
2026-06-15 07:01 · News Release
Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product
2026-06-01 07:02 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2026-03-31
The report says
Revenue
$148,870,119
Net income
$44,872,686
What it means

It earned more than it spent

Steady

After all costs, the company kept $44.9 million as profit in the year.

The report says
Cash and cash equivalents
$29,797,800
Net cash from operating activities
$23,748,094
What it means

The business brings in cash

Steady

Day-to-day business added $23.7 million in cash over the year. It had $29.8 million in the bank.

The report says
Total assets
$138,289,840
Total liabilities
$39,406,865
What it means

It owns more than it owes

Steady

Everything the company owns adds up to $138.3 million. Its debts and unpaid bills add up to $39.4 million. That is about $0.28 owed for every $1 owned.

What this adds up to

0 of 3 checks show strain. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-12

Estimated float about 1,068,204,220 shares as of 2026-11-12: 1,077,569,775 outstanding minus 9,365,555 held by 2 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-12-31
1.07B
2026-02-13
1.08B
2026-03-31
1.08B
2026-06-27
1.08B
2026-06-30
1.08B
2026-08-13
1.08B
2026-09-30
1.08B
2026-11-12
1.08B

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-12 8-K8-K
2026-11-12 10-Q10-Q
2026-11-12 8-K8-K
2026-11-09 3PRIMARY DOCUMENT
2026-11-06 3PRIMARY DOCUMENT
2026-11-03 8-K8-K
2026-10-19 44
2026-09-10 4PRIMARY DOCUMENT
2026-08-13 10-Q10-Q
2026-08-13 8-K8-K
2026-08-11 8-K/A8-K/A
2026-08-10 8-K8-K

Common questions about ELTP

Does ELTP file reports with the SEC?

Yes. Elite Pharmaceuticals INC /nv/ files with the SEC under company number 0001053369. The most recent filing we hold is a 8-K dated 2026-11-12.

Source record

How many ELTP shares are outstanding?

1,077,569,775 shares as of 2026-11-12, as reported to the SEC.

Source record

Has ELTP filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Elite Pharmaceuticals INC /nv/?

Officers named in its insider filings: Douglas Plassche (EVP Operations).

Source record

Is Elite Pharmaceuticals INC /nv/ making money?

After all costs, the company kept $44.9 million as profit in the year. (Annual figures to 2026-03-31. Facts from the company's own report, not a recommendation.)

Source record